NCT06715826View on ClinicalTrials.gov

Target-specific immunoPET Imaging of Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 21, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Breast CancerBreast NeoplasmsBreast Cancer Metastatic
Interventions
DRUG

[68Ga]Ga-NOTA-T4

Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.

DRUG

[18F]F-RESCA-T4

Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.

DRUG

[68Ga]Ga-DOTA-H2D3

Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.

DRUG

[18F]F-RESCA-RB14

Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER